Pfizer begins first human tests of mystery pill PF-07940369
NCT ID NCT07514156
First seen May 01, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-stage study tested a new oral drug called PF-07940369 in 30 healthy adults to see if it is safe and how the body processes it. Participants took the drug or a placebo once or twice daily for 14 days while staying at a clinic. The main goal was to check for side effects and measure drug levels in the blood. This is a first step before testing the drug for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07940369 (oral tablet)
What this could lead to
If this drug is safe, it could move to later trials testing it for a specific disease.
What could go wrong
This is a very early Phase 1 safety study in only 30 healthy people. The drug may not work for any condition or could have side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.